ELAN
Elanco Animal Health Incorporated · Healthcare · Drug Manufacturers - Specialty & Generic
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 104.77K | $2.05M | n/a | −2 |
| Q2 2026 | 128 | +5 | 426.57M | $10.50B | +12 | −8 |
| Q1 2026 | 127 | -2 | 403.59M | $9.65B | +6 | −9 |
| Q4 2025 | 128 | +1 | 433.50M | $9.81B | +4 | −2 |
| Q3 2025 | 20 | -1 | 348.71M | $7.02B | n/a | −2 |
| Q2 2025 | 19 | +2 | 313.01M | $4.47B | +3 | −1 |
| Q1 2025 | 14 | -2 | 167.03M | $1.75B | +1 | −3 |
| Q4 2024 | 16 | -2 | 168.00M | $2.03B | n/a | −2 |
| Q3 2024 | 17 | +1 | 175.40M | $2.58B | +1 | n/a |
| Q2 2024 | 16 | n/a | 207.32M | $2.99B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 83.58M | n/a | $1.21B | 0.7% | n/c | 1 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 52.80M | n/a | $761.94M | 0.6% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 28.07M | n/a | $405.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 12.78M | n/a | $184.41M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 9.42M | n/a | $135.90M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasivo) | 7.80M | n/a | $112.63M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (pasivo) | 3.88M | n/a | $55.95M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.36M | n/a | $48.50M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | D. E. Shaw & Co. ✦ | 2.53M | n/a | $36.53M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 1.40M | n/a | $20.15M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 1.39M | n/a | $19.99M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 160.57K | n/a | $2.32M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 71.23K | n/a | $1.03M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 35.83K | n/a | $517,056 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 24.54K | n/a | $354,170 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 23.11K | n/a | $334,000 | 0.0% | n/c | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Sin salidas rastreadas este trimestre. |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 512 tenedores, 543.55M acciones, $11.98B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Director · 40.00K acc. @ 23.40 · $935,920
Officer · GC AND CORP SEC · 4.00K acc. @ 23.58 · $94,273
Director · 5.00K acc. @ 21.82 · $109,100
Director · 10.00K acc. @ 23.68 · $236,850
Officer · EVP and CFO · 4.20K acc. @ 23.08 · $96,926
Ventas en mercado abierto (S)
Officer · 4.35K acc. · $100,050
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología